Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lineage Cell Therapeutics Inc (NY: LCTX ) 0.8604 -0.0033 (-0.38%) Official Closing Price Updated: 8:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Lineage Cell Therapeutics Inc < Previous 1 2 3 4 5 6 Next > OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D. July 13, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes June 28, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight August 08, 2021 Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... Via Benzinga Exposures Product Safety Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021 August 05, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements July 20, 2021 Lineage Cell Therapeutics Inc (NYSE: LCTX) reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell therapy for dry... Via Benzinga OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy July 20, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing June 22, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Inks Option Agreement With Amasa Therapeutics For HyStem June 17, 2021 Lineage Cell Therapeutics Inc (NYSE: LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to use its... Via Benzinga Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem® June 17, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer June 16, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021 June 15, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index June 09, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen® June 03, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire 68 Biggest Movers From Yesterday June 02, 2021 Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares surged 115.2% to close at $7.64 on Tuesday after the company announced its subsidiary, Gibson Technical Services, reached... Via Benzinga Why Lineage Cell Therapeutics Stock Is Soaring Today June 01, 2021 The company reported great news from a clinical study of its experimental cell therapy for treating eye disease. Via The Motley Fool 36 Stocks Moving In Tuesday's Mid-Day Session June 01, 2021 Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares jumped 67.3% to $5.94 after the company announced its subsidiary, Gibson Technical Services, reached an agreement with TEC... Via Benzinga Lineage Cell Stock Jumps as OpRegen Shows Additional Cases Of Retinal Tissue Restoration In Mid-Stage Study June 01, 2021 Lineage Cell Therapeutics Inc (NYSE: LCTX) has announced that restoration of retinal tissue was observed in two additional patients enrolled in the Phase 1/2a... Via Benzinga Lineage Cell Therapeutics, Inc. (LCTX) Q1 2021 Earnings Call Transcript May 14, 2021 LCTX earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs May 13, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells June 01, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors May 05, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use May 13, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... Via Benzinga Exposures COVID-19 The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings May 09, 2021 Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... Via Benzinga Exposures COVID-19 Product Safety Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021 May 04, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell's Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved Vision May 03, 2021 Lineage Cell Therapeutics Inc (NYSE: LCTX) has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-... Via Benzinga OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy May 03, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021 April 26, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx April 24, 2021 Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... Via Benzinga Exposures Product Safety Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors April 22, 2021 From Lineage Cell Therapeutics, Inc. Via Business Wire Why Lineage Cell Therapeutics Stock Popped Today April 20, 2021 The company announced a license agreement. Via The Motley Fool < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.